EXTRAORDINARY MEASURE

The Ministry of Health, as the competent administrative authority, pursuant to Section 80(1)(g) of Act No. 258/2000 Coll., on public health protection and amendments to certain related acts, as amended, orders this Extraordinary Measure, proceeding pursuant to Section 69(1)(i) and (2) of Act No. 258/2000 Coll., in order to protect the population from the further spread of COVID-19 caused by the novel coronavirus SARS-CoV-2:

I.

Effective from 15 July 2021, all healthcare service providers who were supplied with a medicinal product containing a substance against the COVID-19 disease and purchased from state budget funds based on Commission Decision C(2020) 4192 of 18 June 2020, approving the agreement with Member States on procuring COVID-19 vaccines on behalf of the Member States and related procedures (hereinafter the "provider") are ordered to determine a deadline for administering the second dose of the medicinal product - vaccination substance as follows:

1. COMIRNATY 500MCG/ML INJ CNC DIS 195X0.45ML, Reg. No. EU/1/20/1528/001 SÚKL code 0250256 - date for administering the second dose between 21 and 23 days after administering the first dose,
2. VAXZEVRIA 2.5X10^8INF.U/0.5ML INJ SUS 10X5ML, Reg. No. EU/1/21/1529/002, SÚKL code 0250388 - date for administering the second dose between 84 and 91 days after administering the first dose,
3. SPIKEVAX 0.2MG/ML INJ DIS 10X5ML, Reg. No. EU/1/20/1507/001, SÚKL code 0250303 - date for administering the second dose between 25 and 35 days after administering the first dose,

II.

This Extraordinary Measure takes effect on the date of its issue.

III.

Effective from 15 July 2021, this Extraordinary Measure cancels the Extraordinary Measure of 6 April 2021, Ref. No. MZDR 46953/2020-7/MIN/KAN.

Rationale:

The Extraordinary Measure has been issued in connection with the development of the epidemic situation in terms of the occurrence of the COVID-19 disease, caused by the novel coronavirus designated as SARS-CoV-2 in Europe and the EU. This measure is one of the
important prerequisites for preventing the spread of COVID-19 and is adopted to further accelerate the easing of the extraordinary measures adopted in relation to the epidemic spread of COVID-19 in the population.

The Extraordinary Measure is issued in connection with Extraordinary Measure Ref. No. MZDR 46953/2020-6/MIN/KAN, which introduced a delay between the administration of the first and second dose of the Comirnaty, Moderna and Vaxzevria (then AstraZeneca) vaccines. This extraordinary measure extended the intervals between the first and second dose in order to allow more people to be vaccinated with at least the first dose in a situation of limited supply of vaccines to the Czech Republic.

Given the increased supply of the Spikevax vaccine, the previous extraordinary measure of 7 June 2021 allowed a return to the recommended administration interval of 28 days for the second dose of this vaccine, i.e. an interval of 25 to 35 days.

Given the adequate supply of the Comirnaty vaccine and the expected course of vaccination, as well as the declining number of persons waiting to book an appointment, this Extraordinary Measure shortens the recommended administration interval for the second dose of the vaccine to 21 days, i.e. an interval of 21 to 23 days.

For the Vaxzevria vaccines, the Ministry of Health has decided to continue the administration of the second dose at the interval specified in Extraordinary Measure Ref. No. MZDR 46953/2020-6/MIN/KAN, due to the Opinion of the Czech Vaccinology Society ČLS JEP of 9 February 2021, which states that a longer time interval between individual doses leads to the higher clinical efficacy of the Vaxzevria vaccine.

Mgr. et Mgr. Adam Vojtěch, MHA, undersigned
Minister of Health